{"id":6169,"date":"2025-11-09T05:54:00","date_gmt":"2025-11-09T01:54:00","guid":{"rendered":"https:\/\/omanet.om\/en\/news\/economy\/pfizer-acquires-metsera-obesity-drug\/"},"modified":"2025-11-09T14:59:19","modified_gmt":"2025-11-09T10:59:19","slug":"pfizer-acquires-metsera-obesity-drug","status":"publish","type":"post","link":"https:\/\/omanet.om\/en\/news\/economy\/pfizer-acquires-metsera-obesity-drug\/","title":{"rendered":"Pfizer&#8217;s Acquisition of Metsera: What It Means for the Future of Obesity Drug Investments"},"content":{"rendered":"<style>\r\n@keyframes hitv3sog-fadein{from{opacity:0;transform:translateY(14px)}to{opacity:1;transform:translateY(0)}}\r\n@keyframes hitv3sog-slideup{from{opacity:0;transform:translateY(20px)}to{opacity:1;transform:translateY(0)}}\r\n@keyframes hitv3sog-pulse{0%,100%{box-shadow:0 0 14px #dc262688}50%{box-shadow:0 0 32px #dc2626,0 0 60px #dc262655}}\r\n@keyframes hitv3sog-shimmer{0%,100%{opacity:0.3;transform:scaleX(0.4)}50%{opacity:1;transform:scaleX(1)}}\r\n@keyframes hitv3sog-glow{0%,100%{opacity:0.6}50%{opacity:1}}\r\n@keyframes hitv3sog-badge{from{opacity:0;transform:scale(0.8)}to{opacity:1;transform:scale(1)}}\r\n<\/style><style>\r\n.hitv3sogw{container-type:inline-size;width:100%;max-width:970px;margin:0 auto;box-sizing:border-box}\r\n.hitv3soga{display:flex;flex-direction:row;align-items:center;justify-content:space-between;width:100%;box-sizing:border-box;text-decoration:none;color:#fff;font-family:-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,system-ui,sans-serif;position:relative;overflow:hidden;cursor:pointer;background:linear-gradient(135deg,#111118 0%,#080808 100%);border:1.5px solid rgba(255,255,255,0.08);border-radius:14px;gap:20px;padding:20px 40px;transition:border-color .2s}\r\n.hitv3soga:hover{border-color:#dc262688}\r\n.hitv3sogg1{position:absolute;inset:0;background:radial-gradient(ellipse at 50% 0%,rgba(220,38,38,0.35),transparent 65%);pointer-events:none;z-index:0}\r\n.hitv3sogg2{position:absolute;bottom:0;left:0;right:0;height:45%;background:radial-gradient(ellipse at 50% 100%,rgba(220,38,38,0.15),transparent 70%);pointer-events:none;z-index:0}\r\n.hitv3soggl{position:absolute;top:0;left:8%;right:8%;height:1px;background:linear-gradient(90deg,transparent,#dc262666,transparent);z-index:0}\r\n.hitv3sogc{position:relative;z-index:1;display:flex;flex-direction:column;justify-content:center;flex:1;min-width:0}\r\n.hitv3sogh{font-size:24px;font-weight:800;line-height:1.15;letter-spacing:-.03em;color:#fff;text-shadow:0 2px 12px rgba(0,0,0,.4);margin:2px 0;white-space:nowrap;overflow:hidden;text-overflow:ellipsis}\r\n.hitv3sogs{font-size:13px;color:rgba(255,255,255,.6);line-height:1.4;margin-top:3px;white-space:nowrap;overflow:hidden;text-overflow:ellipsis}\r\n.hitv3sogbl{display:none;flex-direction:column;gap:5px;margin-top:9px;align-self:flex-start}\r\n.hitv3sogbi{display:flex;align-items:center;font-size:11px;color:rgba(255,255,255,.55);font-weight:500}\r\n.hitv3sogct{position:relative;z-index:1;flex-shrink:0;display:flex;flex-direction:column;align-items:center}\r\n.hitv3sogbtn{display:inline-flex;align-items:center;gap:6px;padding:10px 24px;background:#dc2626;background-image:linear-gradient(180deg,rgba(255,255,255,.12) 0%,transparent 100%);color:#fff;font-size:14px;font-weight:700;border-radius:8px;white-space:nowrap;box-shadow:0 0 20px #dc262666;border:none;cursor:pointer;font-family:inherit;transition:filter .15s,transform .15s}\r\n.hitv3sogbtn:hover{filter:brightness(1.15);transform:scale(1.04)}\r\n.hitv3sogbr{font-size:9px;color:rgba(255,255,255,.18);text-align:center;margin-top:5px;letter-spacing:.1em;text-transform:uppercase}\r\n\/* \u2500\u2500 Compact horizontal: 380\u2013599px (like 320\u00d7100) \u2500\u2500 *\/\r\n@container (min-width:380px) and (max-width:599px){\r\n  .hitv3soga{padding:12px 22px;gap:12px;min-height:100px}\r\n  .hitv3sogh{font-size:16px}\r\n  .hitv3sogs{display:none}\r\n  .hitv3sogbtn{padding:7px 16px;font-size:11px}\r\n}\r\n\/* \u2500\u2500 Mobile\/card: < 380px (like 300\u00d7250) \u2500\u2500 *\/\r\n@container (max-width:379px){\r\n  .hitv3soga{flex-direction:column;align-items:center;justify-content:space-between;min-height:260px;padding:22px 22px;gap:10px}\r\n  .hitv3sogc{align-items:center;text-align:center}\r\n  .hitv3sogh{font-size:22px;white-space:normal}\r\n  .hitv3sogs{font-size:11px;white-space:normal}\r\n  .hitv3sogbl{display:flex;align-self:center;text-align:left}\r\n  .hitv3sogbtn{width:100%;justify-content:center;padding:12px 20px}\r\n}\r\n\/* \u2500\u2500 Wide: >= 600px (leaderboard style) \u2500\u2500 *\/\r\n@container (min-width:600px){\r\n  .hitv3soga{min-height:90px}\r\n}\r\n<\/style><!-- HiT Land Banner \u2014 Container Query Responsive -->\r\n<div class=\"hitv3sogw\">\r\n<a class=\"hitv3soga\" href=\"https:\/\/hit.land\/services\/web-app-development\" target=\"_blank\" rel=\"noopener nofollow\" style=\"animation:hitv3sog-fadein 0.7s ease both;animation-delay:0s;\">\r\n  <div class=\"hitv3sogg1\" style=\"animation:hitv3sog-glow 3s ease-in-out infinite;\"><\/div>\r\n  <div class=\"hitv3sogg2\"><\/div>\r\n  <div class=\"hitv3soggl\" style=\"animation:hitv3sog-shimmer 3s ease-in-out infinite;\"><\/div>\r\n  \r\n  <div class=\"hitv3sogc\">\r\n    \r\n    <div style=\"display:inline-flex;align-self:flex-start;align-items:center;gap:6px;background:rgba(255,255,255,0.08);border:1px solid rgba(255,255,255,0.18);backdrop-filter:blur(8px);-webkit-backdrop-filter:blur(8px);border-radius:20px;padding:3px 10px 3px 7px;margin-bottom:clamp(5px,0.6vw,9px);animation:hitv3sog-badge 0.5s ease both;\"><span style=\"display:inline-block;width:6px;height:6px;border-radius:50%;background:#dc2626;flex-shrink:0;\"><\/span><span style=\"font-size:clamp(8px,0.9vw,10px);font-weight:700;letter-spacing:0.07em;color:rgba(255,255,255,0.88);text-transform:uppercase;white-space:nowrap;\">EXCLUSIVE OMAN OFFER<\/span><\/div>\r\n    <div class=\"hitv3sogh\" style=\"animation:hitv3sog-slideup 0.7s ease both;animation-delay:0.15s;\">Websites For <span style=\"color:#dc2626;\">Omani Businesses.<\/span><\/div>\r\n    <div class=\"hitv3sogs\" style=\"animation:hitv3sog-slideup 0.7s ease both;animation-delay:0.3s;\">Empower your brand with custom digital solutions designed for high conversion and market dominance.<\/div>\r\n    <div class=\"hitv3sogbl\"><div class=\"hitv3sogbi\"><span style=\"display:inline-block;width:5px;height:5px;border-radius:50%;background:#dc2626;flex-shrink:0;margin-right:7px;\"><\/span><span>Responsive designs built for growth<\/span><\/div><div class=\"hitv3sogbi\"><span style=\"display:inline-block;width:5px;height:5px;border-radius:50%;background:#dc2626;flex-shrink:0;margin-right:7px;\"><\/span><span>Fast loading with smart automation<\/span><\/div><\/div>\r\n  <\/div>\r\n  \r\n  <div class=\"hitv3sogct\">\r\n    <button class=\"hitv3sogbtn\" style=\"animation:hitv3sog-pulse 2.5s ease-in-out infinite;animation-delay:1s;\">Build Your Free Website <span style=\"opacity:.9;\">\u2192<\/span><\/button>\r\n    <div class=\"hitv3sogbr\">hit.land<\/div>\r\n  <\/div>\r\n<\/a>\r\n<\/div>\n<p>Obesity drug developer Metsera announced on Friday that it has reached an agreement to be acquired by Pfizer, following a competitive bidding war with Danish pharmaceutical company Novo Nordisk, known for its weight-loss treatments Ozempic and Wegovy.<\/p>\n<p>Pfizer will purchase Metsera at a price of up to $86.25 per share, according to a statement from Metsera. This offer slightly surpasses Novo Nordisk\u2019s most recent bid made on Tuesday, which valued Metsera at approximately $10 billion.<\/p>\n<p>This acquisition marks Pfizer\u2019s latest effort to strengthen its position in the growing weight-loss drug market, where it currently trails leaders Novo Nordisk and Eli Lilly, the maker of Mounjaro and Zepbound. It is notable that Metsera\u2019s drug candidates are still undergoing clinical trials.<\/p>\n<p>Pfizer expressed satisfaction with the agreement, stating, \u201cWe are pleased that we and Metsera have agreed to these revised terms, which will provide immediate and certain value to Metsera\u2019s shareholders.\u201d<\/p>\n<p>The current deal\u2019s valuation represents a significant increase from Pfizer\u2019s September offer of $47.50 per share. Novo Nordisk\u2019s subsequent unsolicited bids ignited a fierce competition between the two pharmaceutical giants.<\/p>\n<p>In response to the bidding war, Pfizer filed two lawsuits in the U.S. District Court in Delaware against Metsera and Novo Nordisk. The lawsuits allege breach of contract and anticompetitive conduct. Pfizer further accused Novo Nordisk of attempting to preserve its market dominance by \u201ccapturing and killing a nascent American competitor.\u201d<\/p>\n<p>Novo Nordisk CEO Mike Doustdar addressed the rivalry at a White House press conference on Thursday, stating, \u201cAs of today, our bid is higher, and our message to Pfizer is that if they would like to buy the company then put your hand in the pocket and bid higher.\u201d<\/p>\n<p>On Friday, Metsera revealed it had been advised by the Federal Trade Commission that a transaction with Novo Nordisk could pose substantial legal and regulatory risks under U.S. antitrust laws.<\/p>\n<p>The acquisition is subject to Metsera\u2019s shareholder approval at a meeting scheduled for November 13, after which the deal with Pfizer will be finalized.<\/p>\n<p>This report was originally published by The New York Times.<\/p>\n<p><style>\r\n@keyframes hitl8gak-fadein{from{opacity:0;transform:translateY(14px)}to{opacity:1;transform:translateY(0)}}\r\n@keyframes hitl8gak-slideup{from{opacity:0;transform:translateY(20px)}to{opacity:1;transform:translateY(0)}}\r\n@keyframes hitl8gak-pulse{0%,100%{box-shadow:0 0 14px #dc262688}50%{box-shadow:0 0 32px #dc2626,0 0 60px #dc262655}}\r\n@keyframes hitl8gak-shimmer{0%,100%{opacity:0.3;transform:scaleX(0.4)}50%{opacity:1;transform:scaleX(1)}}\r\n@keyframes hitl8gak-glow{0%,100%{opacity:0.6}50%{opacity:1}}\r\n@keyframes hitl8gak-badge{from{opacity:0;transform:scale(0.8)}to{opacity:1;transform:scale(1)}}\r\n<\/style><style>\r\n.hitl8gakw{container-type:inline-size;width:100%;max-width:970px;margin:0 auto;box-sizing:border-box}\r\n.hitl8gaka{display:flex;flex-direction:row;align-items:center;justify-content:space-between;width:100%;box-sizing:border-box;text-decoration:none;color:#fff;font-family:-apple-system,BlinkMacSystemFont,'Segoe UI',Roboto,system-ui,sans-serif;position:relative;overflow:hidden;cursor:pointer;background:linear-gradient(135deg,#111118 0%,#080808 100%);border:1.5px solid rgba(255,255,255,0.08);border-radius:14px;gap:20px;padding:20px 40px;transition:border-color .2s}\r\n.hitl8gaka:hover{border-color:#dc262688}\r\n.hitl8gakg1{position:absolute;inset:0;background:radial-gradient(ellipse at 50% 0%,rgba(220,38,38,0.35),transparent 65%);pointer-events:none;z-index:0}\r\n.hitl8gakg2{position:absolute;bottom:0;left:0;right:0;height:45%;background:radial-gradient(ellipse at 50% 100%,rgba(220,38,38,0.15),transparent 70%);pointer-events:none;z-index:0}\r\n.hitl8gakgl{position:absolute;top:0;left:8%;right:8%;height:1px;background:linear-gradient(90deg,transparent,#dc262666,transparent);z-index:0}\r\n.hitl8gakc{position:relative;z-index:1;display:flex;flex-direction:column;justify-content:center;flex:1;min-width:0}\r\n.hitl8gakh{font-size:24px;font-weight:800;line-height:1.15;letter-spacing:-.03em;color:#fff;text-shadow:0 2px 12px rgba(0,0,0,.4);margin:2px 0;white-space:nowrap;overflow:hidden;text-overflow:ellipsis}\r\n.hitl8gaks{font-size:13px;color:rgba(255,255,255,.6);line-height:1.4;margin-top:3px;white-space:nowrap;overflow:hidden;text-overflow:ellipsis}\r\n.hitl8gakbl{display:none;flex-direction:column;gap:5px;margin-top:9px;align-self:flex-start}\r\n.hitl8gakbi{display:flex;align-items:center;font-size:11px;color:rgba(255,255,255,.55);font-weight:500}\r\n.hitl8gakct{position:relative;z-index:1;flex-shrink:0;display:flex;flex-direction:column;align-items:center}\r\n.hitl8gakbtn{display:inline-flex;align-items:center;gap:6px;padding:10px 24px;background:#dc2626;background-image:linear-gradient(180deg,rgba(255,255,255,.12) 0%,transparent 100%);color:#fff;font-size:14px;font-weight:700;border-radius:8px;white-space:nowrap;box-shadow:0 0 20px #dc262666;border:none;cursor:pointer;font-family:inherit;transition:filter .15s,transform .15s}\r\n.hitl8gakbtn:hover{filter:brightness(1.15);transform:scale(1.04)}\r\n.hitl8gakbr{font-size:9px;color:rgba(255,255,255,.18);text-align:center;margin-top:5px;letter-spacing:.1em;text-transform:uppercase}\r\n\/* \u2500\u2500 Compact horizontal: 380\u2013599px (like 320\u00d7100) \u2500\u2500 *\/\r\n@container (min-width:380px) and (max-width:599px){\r\n  .hitl8gaka{padding:12px 22px;gap:12px;min-height:100px}\r\n  .hitl8gakh{font-size:16px}\r\n  .hitl8gaks{display:none}\r\n  .hitl8gakbtn{padding:7px 16px;font-size:11px}\r\n}\r\n\/* \u2500\u2500 Mobile\/card: < 380px (like 300\u00d7250) \u2500\u2500 *\/\r\n@container (max-width:379px){\r\n  .hitl8gaka{flex-direction:column;align-items:center;justify-content:space-between;min-height:260px;padding:22px 22px;gap:10px}\r\n  .hitl8gakc{align-items:center;text-align:center}\r\n  .hitl8gakh{font-size:22px;white-space:normal}\r\n  .hitl8gaks{font-size:11px;white-space:normal}\r\n  .hitl8gakbl{display:flex;align-self:center;text-align:left}\r\n  .hitl8gakbtn{width:100%;justify-content:center;padding:12px 20px}\r\n}\r\n\/* \u2500\u2500 Wide: >= 600px (leaderboard style) \u2500\u2500 *\/\r\n@container (min-width:600px){\r\n  .hitl8gaka{min-height:90px}\r\n}\r\n<\/style><!-- HiT Land Banner \u2014 Container Query Responsive -->\r\n<div class=\"hitl8gakw\">\r\n<a class=\"hitl8gaka\" href=\"https:\/\/hit.land\/services\/web-app-development\" target=\"_blank\" rel=\"noopener nofollow\" style=\"animation:hitl8gak-fadein 0.7s ease both;animation-delay:0s;\">\r\n  <div class=\"hitl8gakg1\" style=\"animation:hitl8gak-glow 3s ease-in-out infinite;\"><\/div>\r\n  <div class=\"hitl8gakg2\"><\/div>\r\n  <div class=\"hitl8gakgl\" style=\"animation:hitl8gak-shimmer 3s ease-in-out infinite;\"><\/div>\r\n  \r\n  <div class=\"hitl8gakc\">\r\n    \r\n    <div style=\"display:inline-flex;align-self:flex-start;align-items:center;gap:6px;background:rgba(255,255,255,0.08);border:1px solid rgba(255,255,255,0.18);backdrop-filter:blur(8px);-webkit-backdrop-filter:blur(8px);border-radius:20px;padding:3px 10px 3px 7px;margin-bottom:clamp(5px,0.6vw,9px);animation:hitl8gak-badge 0.5s ease both;\"><span style=\"display:inline-block;width:6px;height:6px;border-radius:50%;background:#dc2626;flex-shrink:0;\"><\/span><span style=\"font-size:clamp(8px,0.9vw,10px);font-weight:700;letter-spacing:0.07em;color:rgba(255,255,255,0.88);text-transform:uppercase;white-space:nowrap;\">EXCLUSIVE OFFER<\/span><\/div>\r\n    <div class=\"hitl8gakh\" style=\"animation:hitl8gak-slideup 0.7s ease both;animation-delay:0.15s;\">Your Website <span style=\"color:#dc2626;\">Should Sell.<\/span><\/div>\r\n    <div class=\"hitl8gaks\" style=\"animation:hitl8gak-slideup 0.7s ease both;animation-delay:0.3s;\">Custom-built websites with smart automation & AI-powered features.<\/div>\r\n    <div class=\"hitl8gakbl\"><div class=\"hitl8gakbi\"><span style=\"display:inline-block;width:5px;height:5px;border-radius:50%;background:#dc2626;flex-shrink:0;margin-right:7px;\"><\/span><span>SEO-optimized & lightning fast<\/span><\/div><div class=\"hitl8gakbi\"><span style=\"display:inline-block;width:5px;height:5px;border-radius:50%;background:#dc2626;flex-shrink:0;margin-right:7px;\"><\/span><span>Smart features built for your business<\/span><\/div><\/div>\r\n  <\/div>\r\n  \r\n  <div class=\"hitl8gakct\">\r\n    <button class=\"hitl8gakbtn\" style=\"animation:hitl8gak-pulse 2.5s ease-in-out infinite;animation-delay:1s;\">Get Free Consultation <span style=\"opacity:.9;\">\u2192<\/span><\/button>\r\n    <div class=\"hitl8gakbr\">hit.land<\/div>\r\n  <\/div>\r\n<\/a>\r\n<\/div><br \/>\n<\/p>\n<p>Special Analysis by Omanet | Navigate Oman&#8217;s Market<\/p>\n<p>Pfizer\u2019s acquisition of Metsera signals <strong>intensified global competition in the weight-loss drug sector<\/strong>, highlighting the immense value investors place on innovative healthcare solutions still in trial phases. For businesses and investors in Oman, this underscores an opportunity to <strong>explore partnerships or investments in cutting-edge biotech and pharmaceutical startups<\/strong>. However, the ongoing legal and regulatory challenges stress the importance of <strong>vigilant risk assessment and strategic positioning in markets subject to intense antitrust scrutiny.<\/strong><\/p>\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer agreed to acquire obesity drug developer Metsera for up to $86.25 per share, winning a bidding war against Novo Nordisk. The deal, worth around $10 billion, targets weight-loss drugs still in trial stages and faces regulatory scrutiny before finalizing post-Nov 13.<\/p>\n","protected":false},"author":10,"featured_media":6170,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[482],"tags":[2722,2721,2723],"class_list":["post-6169","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-economy","tag-metsera-acquisition","tag-pfizer","tag-weight-loss-drugs"],"jetpack_featured_media_url":"https:\/\/omanet.om\/wp-content\/uploads\/2025\/11\/3184384.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/posts\/6169","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/comments?post=6169"}],"version-history":[{"count":1,"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/posts\/6169\/revisions"}],"predecessor-version":[{"id":6171,"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/posts\/6169\/revisions\/6171"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/media\/6170"}],"wp:attachment":[{"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/media?parent=6169"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/categories?post=6169"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/omanet.om\/en\/wp-json\/wp\/v2\/tags?post=6169"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}